Pharma Stock Emcure Pharmaceuticals Jumps 6% to Fresh 52-Week High; Board Meeting for Q4 Results on 5 May

Indian equity markets traded on a strong note on Wednesday, with the Nifty 50 index rising by 292.80 points or 1.22 per cent to 24,288.50 during the session. Amid broad-based buying in healthcare and pharma counters, stock-specific momentum was visible in select pharmaceutical names. In this segment, Emcure Pharmaceuticals' share price surged 6.14 per cent to Rs 1,707 after the company informed that its Board of Directors will meet on May 5, 2026, to consider and approve audited Q4FY26 and FY26 financial results along with recommendation of final Dividend.

Emcure Board Meeting Scheduled for Q4FY26 Results and Dividend

Emcure Pharmaceuticals informed the stock exchanges that a meeting of its Board of Directors is scheduled to be held on Tuesday, May 5, 2026.

The Board will inter alia consider and approve the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The Board will also consider the recommendation of the final dividend, if any, on the equity shares of the company for FY26.

Emcure Pharmaceuticals Shareholding Pattern

As per the March 2026 shareholding pattern, promoter holding in the company stood largely stable at 77.87 per cent compared to 77.87 per cent in the December 2025 quarter.

Foreign Institutional Investors held a 3.35 per cent stake in March 2026 against 3.59 per cent in the previous quarter, while Domestic Institutional Investors maintained their holding at 6.10 per cent. Public shareholding increased to 12.69 per cent from 12.43 per cent sequentially.

The total number of shareholders rose to 1,22,189 as of March 2026 from 1,18,863 in the December 2025 quarter.

About Emcure Pharmaceuticals

Emcure Pharmaceuticals Ltd is one of India’s leading research-driven pharmaceutical companies engaged in the development, manufacturing and marketing of a diversified portfolio of pharmaceutical formulations, biologics and active pharmaceutical ingredients across domestic as well as international markets. The company has established a strong presence across chronic and speciality therapeutic segments with a wide product basket and global regulatory-compliant manufacturing facilities.

The company has a significant footprint in women’s health, cardiology, blood-related therapies, oncology, respiratory care, HIV antivirals, injectables and hospital care products. Backed by strong research capabilities and an expanding global distribution network, Emcure continues to strengthen its position in both branded generics and specialty pharmaceutical businesses across multiple geographies.

Share your thoughts in the comments below.
Disclaimer: This article is for informational purposes only and not investment advice.